Introduction
For patients with non-small cell lung cancer (NSCLC) and no systemic metastasis, mediastinal staging is very important as it provides accurate information on the extent of the disease, it guides the choice of treatment and determines the patient's prognosis.
In 2007 Therefore, the ESTS Council took the initiative to make a revision of the ESTS guidelines on mediastinal staging.
Methodology
The working group had several sessions. The project was discussed in the Council at the ESTS meeting in Essen (June 2012). There were several meetings (Essen, Zürich, Brussels and Birmingham) where the participants presented their experience and discussed the relevant literature published since 2007. Initial findings were presented and discussed at the ESTS meeting in Birmingham (May 2013).
The final paper was put on the website for discussion by all ESTS members. Their remarks will be discussed and included in the final manuscript.
For recommendations, a level of evidence and grading of recommendation is given. This was adapted from the Infectious Disease Society of American-United States Public Health Service Grading System (Table 1; Dykewicz 2001) .
It is evident that both in primary staging and restaging, not every technique is available in every centre. Therefore, staging and restaging techniques can differ between different countries and centres.
Impact of new IASLC lymph node map
There are several modifications compared with the previous Naruke and Mountain and Dresler maps (Naruke 1978, Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718-23) , but probably the most important modification from the clinical point of view is the shift of the anatomic mediastinal midline to the left paratracheal margin, the so-called mediastinal oncologic midline (Rush, 2009 ). This change is important to be understood by radiologists, bronchocopists, nuclear medicine specialists and surgeons because they have to locate 16-07-2013 3 the nodes correctly. The clinical implications of this shift, that affect exclusively nodal stations 2R, 2L, 4R and 4L (for the rest of the nodal stations, the mediastinal midline remains unchanged) is that involved pretracheal lymph nodes and lymph nodes on the left of the anatomic midline but on right side of the oncologic-midline are classified as N2 in case of right-lung tumours but as N3 in case of left-lung tumours.
Another important modification for mediastinal staging is that the anatomical borders of the LN stations are clearly defined This is especially relevant for the lower border of station 4R and 4L. For the right lower paratracheal lymph nodes (station 4R), the lower border is the lower margin of the azygos vein. On the left side, the lower border of the left paratracheal lymph nodes (station 4L) is the upper rim of the left pulmonary artery. By cervical mediastinoscopy (and by endoscopic techniques), the lymph nodes below the azygos vein and below the upper rim of the pulmonary artery can be biopsied and they should be labeled respectively as 10R and 10L.
Definition of nodal zone and nodal station
A nodal zone is an anatomical area that includes one or several neighbouring nodal stations. The supraclavicular and the subcarinal zones include one nodal station each, station 1 and station 7, respectively. However, the limits of both nodal stations 1 and 7 are wider than they used to be in the previous maps. The other nodal zones include two, three or six nodal stations. It is important to realize that, in theory, a single N2 zone may have from 1 to multiple involved nodes in one or several nodal stations, and the nodes may be small or large. The concept of nodal zones is of especial value for those patients who will not undergo surgical treatment. For those receiving chemotherapy, radiotherapy or their combination, the precise anatomical location of the involved nodes is not so important. So, the nodal zones help locate nodal involvement without having to define the exact anatomical location of the nodes. However, nodal stations are important for those patients in whom surgical treatment is required. Precise nodal location is important preoperatively to guide surgical treatment, and also intra-and postoperatively to indicate further treatment. This is especially relevant in the upper mediastinal zone. The upper mediastinal zone includes six nodal stations that are all encompassed in the radiotherapy field; the exact involved nodal station is not important to administer chemo or radiotherapy. However, whether the right or the left paratracheal nodes are involved or not is important to confirm or rule out N2 or N3 disease and to select patients for surgical (multimodality) treatment. There is controversy on the treatment of N2 disease because of the heterogenenity of nodal involvement. Also patient and tumor characteristics and extent of resection play a role in the selection of treatment modality for these patients. In the IASLC paper (Rush 2007), 4277 of 11619 patients clinically staged as cN2cM0 underwent resection and had information on pN category. Only a subgroup of 2876 patients underwent complete (R0) resection without any induction therapy and had information on nodal location and pN category based on pathological staging from lymphadenectomy. An exploratory analysis on the impact of lymph node zones on survival was performed in a subgroup (N=1992 patients) from this cohort, finding that pathological single N1 zone (pN1a) had better prognosis than multiple pathological N1 zones (pN1b); that the prognosis of multiple pathological N1 zones was the same as that of single pathological N2 zone (pN2a); finally, the prognosis of multiple pathological N2 zones (pN2b) was significantly worse. Five-year survival rates for pN1a, pN1b, pN2a and pN2b were 48%, 35%, 34% and 20%, respectively. These survival data should be interpreted with caution and have already been misinterpreted. It is important to have in mind that these survival analyses were performed in resected patients with pathologically staged tumours and thus based on results from lymphadenectomy: information on nodal status was available from station 2 and from stations 4 through 9 in all contributing institutions. Additionally, all centers but one provided documentation on stations 11 and 12, and most had information on stations 1, 13 and 14, while half of them provided documentation on station 3. (Rusch 2007) Therefore, the results from this highly selected population of patients used for this specific analysis cannot be extrapolated to the clinical staging setting. This is why these data cannot be invoked to propose upfront surgical treatment for patients with presumed clinical single N2 zone determined with the current clinical staging guidelines. No pretreatment test (CT, PET, EBUS, EUS, mediastinoscopy) can be compared with lymphadenectomy, except the lymphadenectomies performed through the transcervical approach (video-assisted mediastinal lymphadenectomy -VAMLA, and transcervical extended mediastinal lymphadenectomy -TEMLA). Therefore there is room for a well-designed prospective study to evaluate the possible role of primary surgery in preoperatively proven single zone or single station N2 disease.
There is a subgroup of patients with pretreatment histologically proven N2 disease who are candidate for surgical multimodality treatment. These patients are treated with induction 16-07-2013 5 chemotherapy or induction chemoradiotherapy. In case of downstaging of the mediastinal lymph nodes or major response in those lymph nodes and in the tumour, resection with systematic nodal dissection can be performed with acceptable morbidity and mortality and rewarding 5-year survival.
There are several prognostic indicators, some of them are related to the primary tumour and others are related to the extent of nodal disease. To include patients for surgical multimodality treatment, the disease should be initially technically resectable. Excluded for surgical multimodality are unresectable disease such as extracapsular disease (can be clearly visualized by mediastinoscopy), or bulky N2 disease based on CT. Fit patients with extracapsular disease and/or bulky N2 disease should be treated with definitive chemoradiotherapy.
Bulky N2 disease is not well defined but it correlates with the radiographic group A, as described in e211s-e250s). This group is defined as mediastinal infiltration where the discrete lymph nodes cannot be distinguished or measured. Bulky is not strictly related to the size of the lymph nodes, but it is considered by this committee that lymph nodes larger than 25 mm short axis will also be defined as bulky disease. Bulky disease can be restricted to a single station but usually represents multistation or multiple zonal involvement. Since this paper deals with preoperative lymph node staging, techniques to obtain histology in bulky mediastinal nodal disease are beyond the scope of this article. Although we should aim for the test with the highest sensitivity and NPV, the working group considers a rate of unforeseen N2 disease of 10% as acceptable. After thorough mediastinal staging this unforeseen N2 is mostly single station resectable nodal disease.
5.1.Imaging techniques

Chest CT-scan
Computer tomography remains important in lung cancer imaging. However, due to its low sensitivity (55%) and specificity (81%) it is impossible to solely rely on CT-scan (Silvestri). CT-scan may help us in selecting the appropriate procedure for tissue sampling due to the anatomical images it provides.
PET-CT scan
The addition of PET to CT results in more accurate lymph node staging than CT alone with an overall sensitivity of 80-90% and specificity of 85-95% (meta-analysis PET-CT). PET-CT has a high NPV for detecting mediastinal nodal disease in peripherally located NSCLC. Exceptions include 1. suspected N1 nodes 2. tumour >3cm 3. centrally located tumour without suspected nodes on CT or PET scan.
-In a study from Japan (Hishada 2008), 30% of 143 patients with N1 disease on CT-scan (lymph node short axis > 1cm) were found to have pathologic N2-N3.
-A recent meta-analysis (Wang 2012) has shown that the negative predictive value of PET-CT for tumours ≤ 3cm was 94% (649 patients) compared to 89% for tumours > 3cm (130 patients 
5.2.Endoscopic techniques
Conventional TBNA.
Although the conventional TBNA technique has been available for almost 3 decades, its use in routine clinical practice has only been adopted by a minority (10- has been reported related to an EBUS-TBNA procedure (Navani AJRCCM22012).
5.3.Surgical staging techniques -Cervical mediastinoscopy
Cervical mediastinoscopy through a pretracheal suprasternal incision was introduced by Carlens in There are only retrospective studies comparing the safety and accuracy of conventional mediastinoscopy with VAM ( Although the videomediastinoscope is not strictly necessary to achieve a thorough, clinically acceptable mediastinoscopy, it has many advantages over the conventional one: larger and clearer images, the possibility to simultaneously share the procedure with trainees and all the personnel in the operative theatre, the possibility to record the operation for future educational uses and discussion, and the possibility to improve its teaching without compromising the safety or accuracy of the procedure. Moreover it allows bimanual dissection with possibilities to perform nodal dissection and removal rather than sampling or biopsy. This is especially important and technically feasible for the subcarinal LN station. After removal of station 7 LNs, the oesophagus can be clearly visualized ( figure) . The ESTS working group recommends to perform VAM.
-VATS
Although video-assisted thoracoscopic surgery (VATS) can reach almost every mediastinal lymph node station, it is more invasive than cervical mediastinoscopy (it needs double lumen intubation and a chest tube), it is limited by pleural adhesions, and it can only evaluate ipsilateral nodal disease. For the para-aortic lymph nodes (station 6) and the subaortic lymph nodes (station 5), left VATS is a surgical technique that allows obtaining large tissue samples. It is indicated when enlarged PETpositive lymph nodes are visualized at level 5 or 6. These lymph node stations can not be biopsied by routine mediastinoscopy, EBUS-FNA or EUS-FNA. An alternative to VATS is the left anterior mediastinotomy. In some experienced centres, extended mediastinoscopy is performed for these lymph node stations and it gives good negative (table 5) and are probably more studied in detail than after CM or VAM.
These procedures are performed in very experienced centres. For VAMLA mainly problems with recurrent nerve palsy and important scarring with an impact on subsequent resection are reported.
The published data for TEMLA are mainly from one very experienced centre and there are concerns on morbidity and mortality.
For TEMLA and VAMLA we conclude that currently available data regarding its use are limited and, therefore, we do not recommend its use except of clinical trials. We encourage other centres to publish their data with these new staging techniques.
Minimal requirements for mediastinal nodal staging.
The The same applies to the lower mediastinal lymph nodes (station 8 and 9).
Algorithm for primary mediastinal staging
The algorithm for preoperative mediastinal staging is shown in fig. 1 . For NSCLC, both for mediastinal as for distant staging, PET or PET-CT is indicated.
-When there are no enlarged lymph nodes on CT and when there is no uptake in lymph nodes on PET or PET-CT, direct surgical resection with systematic nodal dissection is indicated for tumours≤ 3 Ifonly CT is available, we refer to the algorithm of the 2007 edition of the ESTS guidelines.
Mediastinal restaging after induction therapy
Mediastinal downstaging after induction therapy for locally advanced stage III non-small cell lung cancer (NSCLC) is an important prognostic factor for long-term survival. Patients with persisting mediastinal involvement have a worse prognosis compared to patients with proven mediastinal downstaging.
The same techniques used in primary staging can be used for mediastinal restaging. Noninvasive imaging techniques are not accurate enough for mediastinal restaging. PET provides additional metabolic information, but there are conflicting data regarding its use. PET has been shown to be more accurate in predicting the T component than the N status [Port 2004 ]. Although experience is rather limited, integrated PET-CT combining precise anatomical and functional information seems to be more accurate for restaging (De Leyn, 2006) . In a prospective study of 93 patients who were restaged by chest CT and integrated PET-CT after induction chemoradiotherapy, repeat PET-CT was Only one study reported the results of VATS for restaging after induction therapy [Jaklitsch MT, 2013] . In this CALGB 39803 trial a negative result of VATS was defined as negative lymph node biopsies from at least 3 lymph node stations, whereas a positive result consisted of a pathological proof of persisting N2 disease or the demonstration of pleural carcinomatosis. Sensitivity, specificity and NPV of VATS for restaging were 67, 100 and 73%, respectively. Restaging by VATS is feasible but requires single-lung ventilation and is limited to one hemithorax only.
An alternative approach that needs prospective validation is to rely on endosonography for baseline mediastinal nodal staging and a first mediastinoscopy for restaging after induction therapy. In this 'restaging' setting the NPV of "a first and more easy and safe mediastinoscopy" was 90% (with a prevalence of ypN2 of 46%, Lardinois 2003).
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We conclude that optimal mediastinal lymph node staging is a truly multidisciplinary process, with a variety of possible techniques, to be performed by experienced hands. 
